Roche, Takeda and Agios Pharmaceuticals are among the sponsors that may this week present before the European Medicines Agency to explain why their respective drugs – faricimab, mobocertinib and mitapivat – should be approved for marketing across the EU.
Faricimab, mobocertinib and mitapivat are among six drugs for which their sponsors are listed as being due, or possibly due,...








